Top Markets
#1 Helium Helium +57.25%
#2 Seeker Seeker +36.80%
#3 Pons Pons +26.62%
#4 TENDIES TENDIES +24.40%
#5 Zylo Ecosystem Zylo Ecosystem +24.40%
#6 UnifAI Network UnifAI Network +21.04%
#7 Bounce Bounce +20.57%
#8 Zora Zora +14.78%
#9 DAPPOS DAPPOS +13.42%
#10 ZKsync ZKsync +12.91%
Coin of the day
Helium Helium
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Poseida Therapeutics, Inc. Poseida Therapeutics, Inc.

Poseida Therapeutics, Inc.

PSTX
Classement en actions #10560
Poseida Therapeutics, Inc., a San Diego-based clinical-stage biopharmaceutical... Poseida Therapeutics, Inc., a San Diego-based clinical-stage biopharmaceutical firm established in 2014, is dedicated to advancing novel therapeutic solutions for conditions with significant unmet medical needs. Its pipeline prominently features several advanced cell therapies. For instance, P-PSMA-101, an autologous CAR-T cell therapy, is currently undergoing Phase I clinical trials for individuals battling metastatic castrate-resistant prostate cancer (mCRPC). Additionally, Poseida is progressing two other CAR-T candidates through Phase I: P-BCMA-ALLO1 targets relapsed/refractory multiple myeloma, while P-MUC1C-ALLO1 is designed to address a variety of solid tumors, such as breast, ovarian, and other epithelial-derived malignancies. The company is further exploring allogeneic (off-the-shelf) CAR-T approaches with candidates like P-CD19CD20-ALLO1, aimed at B cell malignancies and certain autoimmune conditions, and P-BCMACD19-ALLO1, which is in preclinical development for multiple myeloma. Another allogeneic CAR-T, P-PSMA-ALLO1, is also being developed for mCRPC. Beyond cell therapies, Poseida's portfolio includes clinical-stage liver-directed gene therapies, specifically P-OTC-101 and P-FVIII-101, alongside other exploratory allogeneic dual CAR candidates. Collaborative efforts include a research and licensing agreement with Takeda Pharmaceutical Company Limited.
Prix de l'action
$9.50
Dernière synchronisation: 2025-01-08
Capitalisation boursière
$819.52M
Changement (1 jour)
0.00%
Changement (1 an)
0.00%
Pays
US
Échange Poseida Therapeutics, Inc. (PSTX)

Catégorie

Healthcare
EPS pour Poseida Therapeutics, Inc. (PSTX)
EPS au September 2024 TTM : $-0.63
Selon les derniers rapports financiers et le cours de l'action de Poseida Therapeutics, Inc., l’EPS actuel de la société (TTM) est de $-0.63. À la fin de 2022, la société avait un EPS de $-0.89 une diminution par rapport à celui de 2021, qui était de $0.07.
Historique de l'EPS de Poseida Therapeutics, Inc. de 2016 à 2026
EPS à la fin de chaque année
Année EPS Changez
2026 (TTM) $-0.63 -54.01%
2023 $-1.37 53.93%
2022 $-0.89 -1,357.06%
2021 $0.07 68.57%
2020 $0.04 -101.80%
2019 $-2.33 87.90%
2018 $-1.24 153.06%
2017 $-0.49 535.54%
2016 $-0.08 0.00%
EPS pour des entreprises ou concurrents similaires
Entreprise EPS Différence d’EPS Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $17.32 -2,849.21%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $27.74 -4,503.17%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $-5.29 739.68%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $-7.98 1,166.67%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH